Premium
Topical diclofenac in hyaluronan gel for the treatment of solar keratoses
Author(s) -
Gebauer Kurt,
Brown Pam,
Varigos George
Publication year - 2003
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1046/j.1440-0960.2002.00635.x
Subject(s) - medicine , diclofenac , placebo , lesion , dermatology , target lesion , chemotherapy , randomized controlled trial , surgery , gastroenterology , urology , anesthesia , pathology , alternative medicine , percutaneous coronary intervention , myocardial infarction
SUMMARY This randomized, double‐blind, placebo‐controlled study assessed the efficacy and safety of a topical gel containing 3% diclofenac in 2.5% hyaluronan in 150 patients with solar keratoses (SK). The active treatment was compared with the vehicle only, hyaluronan gel, as placebo over a 12‐week period. Patients in both groups applied the active treatment or placebo to a targeted area of skin (0.25 g b.d.). At 12 weeks the mean lesion‐count reduction in the targeted area was not significantly different between treatments. However, at post‐termination follow up (16 weeks), there was a highly significant decrease in the number of lesions, 6.2 ± 7.5 standard deviations (SD) (56.1% reduction) in the active treatment group compared with 2.4 ± 4.3 SD (23.6% reduction) in the placebo group ( P < 0.001). Other efficacy measures (complete lesion resolution, >50% lesion reduction) were also significantly different ( P < 0.01) between treatments at 16 weeks. In conclusion, topical 3% diclofenac in 2.5% hyaluronan gel was effective and well tolerated in this study, suggesting a role for this therapy in the treatment of SK.